|
|
Post by bthomas55ep on Apr 18, 2016 18:54:58 GMT -5
While the Sanofi partnership was extremely painful, I can't help but think just how important it has been for Mannkind to really learn how to commercialize a product. Prior to learning from Sanofi (good and bad), they were simply a manufacturing company. If, and that is still a big if, Afrezza becomes a blockbuster, going it alone will create much more value for shareholders in the long run. T/S Product 2, 3, and 4 will be a breeze when the sales organization structure is in place.
I can't help but think the joint planning meetings, the process of actually getting the product in the channel, the ideas gained about potential marketing strategies, the production of materisls for education and marketing, the work with the payers, etc was tremendous education in its own right to the company. All of that now belongs to Mannkind. The product had been rolled out and scripts are being filled.
It is exciting to see the possibilities now and I don't know if the company really saw a way (or believed they even had the wherewithal or expertise) before Sanofi. Looking forward to see what tomorrow brings.
|
|
|
|
Post by fofos2000i on Apr 19, 2016 8:07:48 GMT -5
MannKind Expands Commercial Capabilities With Two New Hires investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=965732VALENCIA, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced two senior appointments to its commercial organization. Joining the Company are Joseph Saldanha as Vice President of Marketing and Agustin (Tino) Quintero as Vice President of Market Value, Access and Trade. Both will report to Michael Castagna, MannKind's Chief Commercial Officer. "I am excited to have Joe and Tino join my team to help us transition into a commercial organization with dedicated capabilities," said Michael Castagna. "Each brings a wealth of experience in commercialization, diabetes and pharmaceutical product launches, and their skills will be critical as MannKind moves forward with our commercial plans." Matthew Pfeffer, Chief Executive Officer of MannKind added, "The expansion of Mike's organization with these two key roles supports MannKind's business objectives for 2016 and beyond. Under Joe and Tino's leadership, MannKind can develop strong relationships with payors that benefit patients, and produce innovative and focused marketing and sales programs that establish MannKind's market presence with Technosphere®-based products." Mr. Saldanha has worked in the diabetes space for over 13 years, in both U.S. and global roles. He has experience marketing oral anti-diabetic medications, insulins (both injectable and inhaled), and medical devices. Mr. Saldanha commercialized Sanofi's Lantus® in the Intercontinental Region. After returning to the U.S., he was part of the team that commercialized the Lantus SoloSTAR® pen. In addition to heading up Sanofi's strategy and medical education teams, he was responsible for all hospital business. Mr. Saldanha launched an initiative with Certified Diabetes Educators® to train patients in diabetes and the appropriate use of insulin. Prior to that, Mr. Saldanha served as Director of Business Development for the insulin delivery device business at Johnson and Johnson Diabetes (LifeScan®/Animas®). More recently, he worked in the biosimilars business with Pfizer in New York. Mr. Saldanha holds a Bachelor of Science from Drexel University and a Master of Science from the University of Pennsylvania. Mr. Quintero has 18 years of experience in bio-pharmaceutical market access as well as a proven record of achieving commercial excellence. He joins MannKind from AbbVie, a global biopharmaceutical company, where he served as National Managed Care Executive. In this role, Mr. Quintero was responsible for negotiating AbbVie's portfolio of products (including Humira®) while developing contracting and pricing strategies for hepatitis C, multiple sclerosis and oncology product launches. Prior to that, he held integral leadership roles in sales and account management at Vertex Pharmaceuticals, including oversight of the commercial launch of Incivek®, their first commercial product. Earlier, he was part of Gilead Sciences and Sandoz's leadership teams, responsible for sales, product launches and market access for both commercial and government payers. Mr. Quintero holds a Bachelor of Science in economics from Florida International University. |
|
|
|
Post by kball on Apr 19, 2016 8:26:00 GMT -5
Might need a mod to do some thread consolidation. Currently 3 covering hires today
|
|
|
|
Post by lakon on Apr 19, 2016 11:45:09 GMT -5
"...going it alone will create much more value for shareholders in the long run. T/S Product 2, 3, and 4 will be a breeze when the sales organization structure is in place."
Believe it! Survive and thrive!
Don't forget that Epinephrine won't take that long.
“Whether you think you can, or you think you can't--you're right.”
― Henry Ford
|
|
|
|
Post by bradleysbest on Apr 19, 2016 12:12:19 GMT -5
If Afrezza 2.0 takes off under the new regime someone will make an offer for MNKD. Great points but I don't see MNKD marketing the next TS products for that reason.
|
|
|
|
Post by lakon on Apr 19, 2016 12:30:16 GMT -5
If Afrezza 2.0 takes off under the new regime someone will make an offer for MNKD. Great points but I don't see MNKD marketing the next TS products for that reason. Except that MNKD already said that Epinephrine is their baby. The other 2 of the next 3 would be partnered. They are a drug development company and now building a full on commercial marketing engine. We are now in Al Mann's Legacy Mode. He always said that they could do it themselves IF NEEDED. SNY proved that it is needed. Those that inherited MNKD are very unlikely to sell out the ol' Mann's Legacy. Therefore, they do a shelf registration to shore up resources and defend against hostile forces. You'd better hunker down if you are going to hold because a quick sale is not in the cards IMO. Watch for the flurry of activity.  |
|
|
|
Post by jerrys on Apr 19, 2016 13:07:16 GMT -5
While the Sanofi partnership was extremely painful, I can't help but think just how important it has been for Mannkind to really learn how to commercialize a product. Prior to learning from Sanofi (good and bad), they were simply a manufacturing company. If, and that is still a big if, Afrezza becomes a blockbuster, going it alone will create much more value for shareholders in the long run. T/S Product 2, 3, and 4 will be a breeze when the sales organization structure is in place. I can't help but think the joint planning meetings, the process of actually getting the product in the channel, the ideas gained about potential marketing strategies, the production of materisls for education and marketing, the work with the payers, etc was tremendous education in its own right to the company. All of that now belongs to Mannkind. The product had been rolled out and scripts are being filled. It is exciting to see the possibilities now and I don't know if the company really saw a way (or believed they even had the wherewithal or expertise) before Sanofi. Looking forward to see what tomorrow brings. "I can't help but think the joint planning meetings, the process of actually getting the product in the channel, the ideas gained about potential marketing strategies, the production of materisls for education and marketing, the work with the payers, etc was tremendous education in its own right to the company."
I have to wonder whether if there ever were any JAC meetings or at least any meetings that MNKD attended. They have never said anything about what happened at those meetings, and I don't believe I've seen anywhere them saying that they claim having learned anything from those meetings. Moreover, if there was anything to be learned, why didn't SNY learn it and use it?
Another thing is that I can't find a single pharmaceutical distributor that carries afrezza. I checked Henry Schein's catalog as well as a number of smaller distributors. It seems like a logical first step would be to get afrezza into the distributor catalogs. That certainly shouldn't cost much and would make it more readily available to hospitals, pharmacies, PCPs, etc.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 19, 2016 13:15:12 GMT -5
While the Sanofi partnership was extremely painful, I can't help but think just how important it has been for Mannkind to really learn how to commercialize a product. Prior to learning from Sanofi (good and bad), they were simply a manufacturing company. If, and that is still a big if, Afrezza becomes a blockbuster, going it alone will create much more value for shareholders in the long run. T/S Product 2, 3, and 4 will be a breeze when the sales organization structure is in place. I can't help but think the joint planning meetings, the process of actually getting the product in the channel, the ideas gained about potential marketing strategies, the production of materisls for education and marketing, the work with the payers, etc was tremendous education in its own right to the company. All of that now belongs to Mannkind. The product had been rolled out and scripts are being filled. It is exciting to see the possibilities now and I don't know if the company really saw a way (or believed they even had the wherewithal or expertise) before Sanofi. Looking forward to see what tomorrow brings. "I can't help but think the joint planning meetings, the process of actually getting the product in the channel, the ideas gained about potential marketing strategies, the production of materisls for education and marketing, the work with the payers, etc was tremendous education in its own right to the company."
I have to wonder whether if there ever were any JAC meetings or at least any meetings that MNKD attended. They have never said anything about what happened at those meetings, and I don't believe I've seen anywhere them saying that they claim having learned anything from those meetings. Moreover, if there was anything to be learned, why didn't SNY learn it and use it?
Another thing is that I can't find a single pharmaceutical distributor that carries afrezza. I checked Henry Schein's catalog as well as a number of smaller distributors. It seems like a logical first step would be to get afrezza into the distributor catalogs. That certainly shouldn't cost much and would make it more readily available to hospitals, pharmacies, PCPs, etc.
Henry Schein, Inc., a FORTUNE 500® company and a member of the S&P 500® and NASDAQ 100® Indices, is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners |
|
|
|
Post by me on Apr 19, 2016 13:24:43 GMT -5
While the Sanofi partnership was extremely painful, I can't help but think just how important it has been for Mannkind to really learn how to commercialize a product. Prior to learning from Sanofi (good and bad), they were simply a manufacturing company. If, and that is still a big if, Afrezza becomes a blockbuster, going it alone will create much more value for shareholders in the long run. T/S Product 2, 3, and 4 will be a breeze when the sales organization structure is in place. I can't help but think the joint planning meetings, the process of actually getting the product in the channel, the ideas gained about potential marketing strategies, the production of materisls for education and marketing, the work with the payers, etc was tremendous education in its own right to the company. All of that now belongs to Mannkind. The product had been rolled out and scripts are being filled. It is exciting to see the possibilities now and I don't know if the company really saw a way (or believed they even had the wherewithal or expertise) before Sanofi. Looking forward to see what tomorrow brings. "I can't help but think the joint planning meetings, the process of actually getting the product in the channel, the ideas gained about potential marketing strategies, the production of materisls for education and marketing, the work with the payers, etc was tremendous education in its own right to the company."
I have to wonder whether if there ever were any JAC meetings or at least any meetings that MNKD attended. They have never said anything about what happened at those meetings, and I don't believe I've seen anywhere them saying that they claim having learned anything from those meetings. Moreover, if there was anything to be learned, why didn't SNY learn it and use it?
Another thing is that I can't find a single pharmaceutical distributor that carries afrezza. I checked Henry Schein's catalog as well as a number of smaller distributors. It seems like a logical first step would be to get afrezza into the distributor catalogs. That certainly shouldn't cost much and would make it more readily available to hospitals, pharmacies, PCPs, etc.
, I checked staples.com and couldn't find Afrezza there either. I guess that means nothing but dark, dark days ahead! |
|
|
|
Post by end2war on Apr 19, 2016 15:09:05 GMT -5
My question is whether they can project how much a typical sales rep can generate in scripts per month? Is there a usable mathematical relationship between the number of reps and the number of scripts, and when, and to what extent should the growing sales pay for the cost of the reps? I suppose they have some kind of financial model for how the sales should ramp, if they hit their targets. Then they will watch who does and who does not achieve the targeted scripts. I wonder if they will reveal their plans for how they expect sales to ramp, once their marketing group get started.
|
|
|
|
Post by peppy on Apr 19, 2016 15:25:00 GMT -5
My question is whether they can project how much a typical sales rep can generate in scripts per month? Is there a usable mathematical relationship between the number of reps and the number of scripts, and when, and to what extent should the growing sales pay for the cost of the reps? I suppose they have some kind of financial model for how the sales should ramp, if they hit their targets. Then they will watch who does and who does not achieve the targeted scripts. I wonder if they will reveal their plans for how they expect sales to ramp, once their marketing group get started. target number 1 the old script highs and sweedee's dad mnkd.proboards.com/attachment/download/1797
|
|
|
|
Post by sportsrancho on Apr 19, 2016 17:33:42 GMT -5
"...going it alone will create much more value for shareholders in the long run. T/S Product 2, 3, and 4 will be a breeze when the sales organization structure is in place." Believe it! Survive and thrive! Don't forget that Epinephrine won't take that long. “Whether you think you can, or you think you can't--you're right.” ― Henry Ford When you can't go right, go left!--mnholdem |
|
|
|
Post by mnholdem on Apr 19, 2016 18:59:27 GMT -5
I cannot believe you remembered that favorite saying of mine. You must have an awesome memory.  I'm thinking the team at MannKind gets it and will navigate Afrezza around the roadblocks.  |
|
|
|
Post by brotherm1 on Apr 19, 2016 20:24:53 GMT -5
"...going it alone will create much more value for shareholders in the long run. T/S Product 2, 3, and 4 will be a breeze when the sales organization structure is in place." Believe it! Survive and thrive! Don't forget that Epinephrine won't take that long. “Whether you think you can, or you think you can't--you're right.” ― Henry Ford When you can't go right, go left!--mnholdem |
|
|
|
Post by brotherm1 on Apr 19, 2016 20:40:49 GMT -5
I greatly appreciate this board and give thanks to the many constructive posters and the hard working administrators. Although I have been reading much about MNKD, both before and now after I purchased shares about a month ago, I still have a lot to learn about the company. Regading the above posted:
"Don't forget that Epinephrine won't take that long."
Does anyone have an approximate time frame for this TS Epinephrine to be on the market and the approximate market value for it in the US and perhaps for foreign countries where it might be applicable?
|
|
